Abstract
Background: Antithrombin (AT) is one of the most important regulator of hemostasis. AT Budapest 3 (ATBp3) is a prevalent type II heparin-binding site (IIHBS) deficiency due to founder effect. Thrombosis is a complex disease including arterial (ATE) and venous thrombotic events (VTE) and the Roma population, the largest ethnic minority in Europe has increased susceptibility to these diseases partly due to their unfavorable genetic load. We aimed to calculate the age and origin of ATBp3 and to explore whether the frequency of it is higher in the Roma population as compared with the general population from the corresponding geographical area. We investigated the association of ATBp3 with thrombotic events in well-defined patients' populations in order to refine the recommendation when testing for ATBp3 is useful.Methods and Results: Prevalence of ATBp3, investigated in large samples (n = 1,000 and 1,185 for general Hungarian and Roma populations, respectively) was considerably high, almost 3%, among Roma and the founder effect was confirmed in their samples, while it was absent in the Hungarian general population. Age of ATBp3—as calculated by analysis of 8 short tandem repeat sequences surrounding SERPINC1—was dated back to XVII Century, when Roma migration in Central and Eastern Europe occurred. In our IIHBS cohort (n = 230), VTE was registered in almost all ATBp3 homozygotes (93%) and in 44% of heterozygotes. ATE occurred with lower frequency in ATBp3 (around 6%); it was rather associated with AT Basel (44%). All patients with ATE were young at the time of diagnosis. Upon investigating consecutive young (<40 years) patients with ATE (n = 92) and VTE (n = 110), the presence of ATBp3 was remarkable.Conclusions: ATBp3, a 400-year-old founder mutation is prevalent in Roma population and its Roma origin can reasonably be assumed. By the demonstration of the presence of ATBp3 in ATE patients, we draw the attention to consider type IIHBS AT deficiency in the background of not only VTE but also ATE, especially in selected populations as young patients without advanced atherosclerosis. We recommend including the investigation of ATBp3 as part of thrombosis risk assessment and stratification in Roma individuals.
Highlights
Thrombosis is a common complex disease including arterial thrombotic diseases as myocardial infarction (MI), ischemic stroke (IS), or peripheral arterial occlusive disease and venous thrombotic events (VTE), which are the major contributors of morbidity and mortality in all developed countries [1]
Age and Origin of the Type II heparin-binding site (IIHBS) Antithrombin Budapest 3 Mutation As the founder effect of AT Budapest 3 (ATBp3) mutation was confirmed previously, we aimed to investigate the age and origin of the most recent common ancestor (MRCA) of the ATBp3 (c.391C>T) and to provide a plausible historical and demographic scenario in which the founder effect could have started
The mean ± SD overall age estimate for the SERPINC1 c.391C>T mutation, based on the Linkage disequilibrium (LD) data for the eight short tandem repeat (STR), was 11.5 ± 5.47 g according to the first moment method (Table 1) and it was 11.8 ± 7.1 g according to the iterative procedure of the second one
Summary
Thrombosis is a common complex disease including arterial thrombotic diseases as myocardial infarction (MI), ischemic stroke (IS), or peripheral arterial occlusive disease and venous thrombotic events (VTE), which are the major contributors of morbidity and mortality in all developed countries [1]. Heparinbinding site (HBS) of AT encoded by exon 2 of SERPINC1 (the gene encoding AT) is responsible for the interaction between heparins and AT [2] Mutations in this region lead to functional AT deficiency, namely, type IIHBS with decreased heparinAT interaction. The first-line laboratory assay in the diagnosis of AT deficiency is a functional amidolytic test in which the inhibitory effect of AT on active FXa or thrombin is investigated in the presence of heparin [14, 15]. This assay shows reduced AT activity in all AT deficiency types, including type II variants. We investigated the association of ATBp3 with thrombotic events in well-defined patients’ populations in order to refine the recommendation when testing for ATBp3 is useful
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
